FindTrial
Sign In

Postmarketing clinical study on AG-1749-clinical study on non-erosive reflux disease-

-

Status
Unknown
Phases
Phase 4
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT1080221028
Enrollment
Unknown
Registered
2010-02-24
Start date
2010-02-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-erosive reflux disease

Interventions

investigational material(s) Generic name etc : AG-1749(Lansoprazole) INN of investigational material : Therapeutic category code : 232 Agents for peptic ulcer Dosage and Administration for Investigat

Sponsors

Takeda Pharmaceutical Company Limited
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Subjects who have repeated acid reflux symptoms(chest burn or water brash)for two days or more in a week for 3 weeks prior to the running period. 2.Subjects shown by endoscopy not to have erosive or ulcerative esophagitis 3.Subjects have given written informed consent to participate in this study.

Exclusion criteria

Exclusion criteria: 1.Subjects complicated with acute gastritis or chronic gastritis in the acute phase of worsening. 2.Subject with a history of surgery (such as upper gastrointestinal tract dissection or vagotomy) that affects gastric acid secretion.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026